Correspondence on ‘Low-dose Thrombolysis for Submassive Pulmonary Embolism’ by Yilmaz and Uzun

Abstract

Keywords

Pulmonary Embolism

Get full access to this article

View all access options for this article.

References

Yilmaz

, Uzun

. Low-dose thrombolysis for submassive pulmonary embolism. J Investig Med 2021;69:1439–46.doi:10.1136/jim-2021-001816http://www.ncbi.nlm.nih.gov/pubmed/34099544

Konstantinides

, Meyer

, Becattini

. ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2019;2020:543–603.

INSPIRATION Investigators, Sadeghipour

, Talasaz

, . Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021;325:1620–30.doi:10.1001/jama.2021.4152http://www.ncbi.nlm.nih.gov/pubmed/33734299

Chatterjee

, Chakraborty

, Weinberg

, . Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014;311:2414–21.doi:10.1001/jama.2014.5990http://www.ncbi.nlm.nih.gov/pubmed/24938564

Piazza

. Advanced management of intermediate- and high-risk pulmonary embolism: JACC focus seminar. J Am Coll Cardiol 2020;76:2117–27.doi:10.1016/j.jacc.2020.05.028http://www.ncbi.nlm.nih.gov/pubmed/33121720

Meyer

, Vicaut

, Danays

, . Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370:1402–11.doi:10.1056/NEJMoa1302097http://www.ncbi.nlm.nih.gov/pubmed/24716681

Rothschild

, Goldstein

, Bowers

. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: clinical efficacy but attendant hemorrhagic risks. Catheter Cardiovasc Interv 2019;93:506–10.doi:Alteplasehttp://www.ncbi.nlm.nih.gov/pubmed/30549393

Sharifi

, Bay

, Skrocki

, . Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013;111:273–7.doi:10.1016/j.amjcard.2012.09.027http://www.ncbi.nlm.nih.gov/pubmed/23102885

Güner

, Kalçik

, Aykan

Ahmet Ç

, . Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism. Blood Coagul Fibrinolysis 2020;31:536–42.doi:10.1097/MBC.0000000000000960http://www.ncbi.nlm.nih.gov/pubmed/33181758